Glionova (private company)

See something wrong or missing? Let us know
Offices:
Stockholm
Category:
Biotech
Business model:
B2B
Key People:
Eugen Steiner
Investors:
we tracked 3 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 1 transaction

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Glionova is a privately held biopharmaceutical company focused on developing new therapies for cancer. The company is engaged in the development of therapies for difficult-to-treat cancers and develops GLN-1001, an orally bioavailable small molecule that induces selective cell death in glioblastoma cells without causing harm to normal brain tissue.

Companies with similar profile to Glionova:

CompanyCriteria
Denmark Reapplix
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Denmark Antag Therapeutics
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Denmark Acesion Pharma
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Sweden BoneSupport
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Industrifonden, HealthCap
Sweden Merozyne Therapeutics
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Sweden Athera
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
Denmark Biosyntia
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Sweden OxThera
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Industrifonden, HealthCap
Sweden eBuilder
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 5M - 10M USD
Sweden Adfenix
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 5M - 10M USD
Sweden Mantex
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 5M - 10M USD
Sweden Burt
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 5M - 10M USD
Sweden Trialbee
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 5M - 10M USD
Sweden AMRA
34%
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds, Industrifonden
  • Total raised in a similar range: 5M - 10M USD
Sweden Now Interact
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 5M - 10M USD
Norway Sorbwater Technology
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
Finland TILT Biotherapeutics
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
Finland Aurealis Pharma
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
Sweden InDex Pharmaceuticals
24%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
Norway poLight
24%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden